{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+%2B+Placebo&page=2",
    "query": {
      "intervention": "SOC + Placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SOC+%2B+Placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T16:47:01.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04619706",
      "title": "Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "FSD201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care for Covid-19",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Quantum Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2020-12-14",
      "completion_date": "2021-08-24",
      "has_results": false,
      "last_update_posted_date": "2022-12-05",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • St. Petersburg, Florida • Idaho Falls, Idaho + 6 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Winfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04619706"
    },
    {
      "nct_id": "NCT04415073",
      "title": "A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus",
        "COVID",
        "ARDS",
        "Cytokine Storm",
        "Cytokine Release Syndrome"
      ],
      "interventions": [
        {
          "name": "SNDX-6352",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndax Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-05-30",
      "completion_date": "2020-07-13",
      "has_results": true,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • The Bronx, New York",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04415073"
    },
    {
      "nct_id": "NCT04372186",
      "title": "A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 377,
      "start_date": "2020-05-14",
      "completion_date": "2020-09-22",
      "has_results": true,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • El Centro, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04372186"
    },
    {
      "nct_id": "NCT07782957",
      "title": "A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nasal Polyps"
      ],
      "interventions": [
        {
          "name": "GSK5784283",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2026-09-03",
      "completion_date": "2029-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 1,
      "location_summary": "Plano, Texas",
      "locations": [
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07782957"
    },
    {
      "nct_id": "NCT04546581",
      "title": "Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID",
        "COVID-19",
        "SARS-CoV-2",
        "SARS (Severe Acute Respiratory Syndrome)"
      ],
      "interventions": [
        {
          "name": "Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 593,
      "start_date": "2020-10-08",
      "completion_date": "2021-05-21",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 18,
      "location_summary": "Colorado Springs, Colorado • Lakewood, Colorado • Westminster, Colorado + 13 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Westminster",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04546581"
    },
    {
      "nct_id": "NCT04058028",
      "title": "Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus (SLE)"
      ],
      "interventions": [
        {
          "name": "Rozibafusp Alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Rozibafusp Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 244,
      "start_date": "2020-02-19",
      "completion_date": "2023-07-25",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04058028"
    },
    {
      "nct_id": "NCT04375397",
      "title": "Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CoronaVirus Induced Disease-2019 (COVID-19)"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2020-06-06",
      "completion_date": "2021-06-08",
      "has_results": true,
      "last_update_posted_date": "2022-06-01",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 9,
      "location_summary": "Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375397"
    },
    {
      "nct_id": "NCT07775300",
      "title": "A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Brenipatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2026-08",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07775300"
    },
    {
      "nct_id": "NCT05132569",
      "title": "Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Tolebrutininb",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-12-03",
      "completion_date": "2023-02-21",
      "has_results": true,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 5,
      "location_summary": "Washington D.C., District of Columbia • Boca Raton, Florida • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05132569"
    },
    {
      "nct_id": "NCT04370262",
      "title": "Multi-site Adaptive Trials for COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SOC + Intravenous Famotidine",
          "type": "DRUG"
        },
        {
          "name": "SOC + Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2020-04-07",
      "completion_date": "2020-09-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-11",
      "last_synced_at": "2026-09-27T16:47:01.855Z",
      "location_count": 5,
      "location_summary": "Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more",
      "locations": [
        {
          "city": "Bay Shore",
          "state": "New York"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "Mount Kisco",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Queens",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04370262"
    }
  ]
}